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Poster Session-I 61transplant, disease status, donor type, absolute neutrophil count, ab-
solute lymphocyte count (ALC), presence of circulating blasts, stem
cell source, CD341 cell dose, conditioning intensity, cytogenetic
profile, antecedent myelodysplastic syndrome (MDS) or secondary
AML, and development of acute graft versus host disease
(GVHD). Deaths attributable to relapse versus non-relapse causes
were recorded for each PFT group.
Results: Pre-transplant characteristics included a median age of
49 yrs (range 7–69 yrs), intermediate/high risk cytogenetics (95%),
CR1/ CR2 (93%), circulating blasts (8%), full intensity conditioning
(78%), related donor (48%), FEV1\ 80% (12%), FVC \ 80%
(15%), and DLCO\ 65% (34%). Diminished FEV1 (\ 80%), dis-
ease status, regimen intensity, ALC, and circulating blasts were asso-
ciated with a significantly reduced disease free survival (Table).
Though FEV1\ 80% and FVC\ 80% were both associated with
a poor DFS (p 5 0.001 and p 5 0.027) and OS (p 5 0.005 and
p5 0.017) by univariate analysis, only FEV1\80% remained asso-
ciated with DFS and OS in the multivariate Cox regression analysis.
Pre-transplant DLCO\ 65% did not reach significance for either
DFS or OS by univariate or multivariate analysis. Relapse related
mortality was more common in patients with a pre-transplant
FEV1 $80% (50%) then patients with an FEV1\80% (39%).
Conclusion: Pre-transplant FEV1\ 80% is associated with re-
duced DFS and OS in patients with AML undergoing allogeneic
HSCT and may provide valuable prognostic information in pre-
transplant evaluations.
Pre-Transplant Factors Associated with Survival
Overall Survival Disease Free SurvivalRisk Factor Risk Ratio p-value Risk Ratio p-valueFEV1$ 80 0.519 0.019 0.467 0.006
Disease Status1 2.144 0.000 1.924 0.004
Regimen Intensity 2 2.174 0.001 2.047 0.003
ALC $ 0.5 0.513 0.003 0.544 0.008
Peripheral Blast 13 - - 2.220 0.0181Disease .CR2 or in relapse.
2reduced intensity conditioning (RIC).
3not associated with overall survival.163
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Introduction: The clinical outcomes of relapsed and refractory
acute myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL) are dismal in adults treated with conventional therapy. The
majority of patients with relapsed ALL and AML who are subse-
quently cured are transplanted in second remission or, occasionally,
beyond second complete remission. A minority of patients, in the
range of 10 to 20%, with relapsed/refractory disease are cured by
an allogeneic bone marrow transplant.
Objective: We retrospectively examined 137 patients with re-
lapsed and/or refractory acute leukemia who were recipients of allo-
geneic transplants (matched related [MRD], matched unrelated
[MUD] and umbilical cord blood [UCB]) at our center from August
1986 to August 2008 to determine the outcome in advanced leuke-
mia.
Methods: One hundred thirty seven patients (AML, n 5 95 and
ALL, n 5 42) received allogeneic transplants including: 75 MRD,
39MUD, and 23UCB.Conditioning regimens weremostlymyeloa-
blative using combinations of cyclophosphamide(Cy), busulfan (Bu),
etoposide(VP) and total body irradiation (TBI): TBI/Cy/VP, n5 31;
TBI/Cy, n5 66; other TBI based, n5 10; Bu/Cy, n5 20;.other, n5
9. GVHD prophylaxis varied over the years but included a calci-
neurin inhibitor with methotrexate for MUD/MRD transplants
and steroids for UCB transplants.Results:The median age at transplant was 45 years for AML (13–
72) and 32 years for ALL (1–66). Results are shown in the table below
and compared to the survival data (extrapolated) from the NMDP/
CIBMTR database.
Table 1 Transplant Outcomes in Relapsed and/or Refractory
Acute Leukemia
NMDP/ NMDP/N100 day
survival1 year
survival2 year
survivalCIBMTR
-MRDCIBMTR
-MUD1 year–
2year1 year–
2yearAML 95 62% 33% 27%MRD 75 68% 30% 22% 40%–30%MUD 39 54% 30% 26% 30%–20%UCB 23 48% 26% 16%Survival by Age\40yrs 35 74% 48% 38%
40–55yrs 36 56% 29% 26%.55yrs 24 54% 12% 12%ALL 42 57% 21% 11% 35%–20% 30%–15%Conclusion: Our single institutional experience in allogeneic
transplantation for advanced leukemia appears comparable to the
CIBMTR/NMDP database. Younger patients had the best out-
comes. MUD recipients had comparable outcomes to MRD. There-
fore, we recommend that younger patients with advanced leukemia
be strongly considered for allogeneic transplant, regardless of stem
cell source, as the only potentially curative option.164
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Adoptive transfer of T cells has been used to treat and prevent ma-
lignancies and opportunistic infections. To improve therapuetic effi-
cacy, investigators initially redirected specificity through the
introduction of immunoreceptors. Early-phase trials are now under-
way to demonstrate the safety and feasibility ofCD19-specific chime-
ric antigen receptors (CARs)which recognize antigen independent of
MHC. However, it is recognized that improving in vivo persistence
will be needed to enhance therapeutic potential of CAR1 T cells.
To this end we developed two approaches: (i) intrinsic: altering the
signalling pathway of T cells to improve persistence and (ii) extrinsic:
altering the culturing milieu to numerically expand CAR1 T cells
with a proliferative advantage. Previously we reported on a 2nd gen-
eration CAR (designated CD19RCD28) which activates T cells
through CD3-z and CD28 endodomains, to sustain proliferation of
CD19-specific T cells. One extrinsic factor to be assessed is IL-21,
a member of the common g-chain receptor cytokine family that can
signal CD81T cells in conjunction with CD28 to support prolifera-
tion and acquisition of desired effector functions.Wenow report that
the addition of exogenous IL-21 favors the microenvironment to se-
lectively propagate CAR1 CD81 T cells with ability to kill CD191
tumor targets. To evaluate this role for IL-21, peripheral blood-de-
rived T cells were electroporated with CD19RCD28 CAR expressed
as a Sleeping Beauty (SB) transposon and propagated in the presence of
IL-2 and/or IL-21 on g-irradiated CD191 artificial antigen present-
ing cells (aAPC). There was a selective outgrowth of CAR1CD81T
cells when IL-21 was present in the culture medium, compared with
predominant outgrowth of CAR1CD41T cells when IL-21 was ab-
sent (Table).The propagatedCAR1Tcells producedmore IFN-g in
response toCD191 stimulator cells compared to cells cultured in par-
allel only on IL-2, and displayed a centralmemory surface phenotype
while retaining an ability to exhibit CD19-dependent cytolysis.
